B-cell problems in chronic inflammatory demyelinating polyneuropathy (CIDP)
Official title: In-depth characterization of B-cell dysfunction in chronic inflammatory demyelinating polyneuropathy
Funded at Yale University · NIH-11308721 · Data updated 2026-11-12
Researchers are looking at how B cells and the antibodies they make may damage nerves in people with CIDP to help guide better treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $410,581 |
| NIH project number | 5R01NS132860-03 |
| Project ID | NIH-11308721 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults diagnosed with CIDP who are willing to provide blood samples (and possibly nerve biopsy material or clinical data) and share treatment history.
✕Less likely to help
People without CIDP or with neuropathies that are not autoimmune in nature are unlikely to benefit from this research.
What this research studies
If you join, researchers may collect blood and, in some cases, nerve tissue to look for the types and targets of antibodies in people with CIDP. They will compare patients who have known nodal/paranodal autoantibodies to those who do not and measure B-cell features and antibody effects. Lab and animal tests may be used to see whether patient antibodies can injure nerves or slow nerve signals. The goal is to find markers that predict who might respond to B-cell–targeting therapies.
Why it matters
Potential benefit: This work could help identify specific antibody-driven forms of CIDP and point to treatments, like B-cell–targeting therapies, that are more likely to work for particular patients.
How similar studies have gone: Prior work has identified autoantibodies against nodal/paranodal proteins and shown that some patients with those antibodies do better with B-cell depletion, but many CIDP patients still lack a known antibody and need more answers.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Roy, Bhaskar — Yale University
- Study coordinator: Roy, Bhaskar
Related research
Other NIH-funded projects on the same topics.
-
Small skin sample to help detect and track CIDP
This project tests whether a tiny skin biopsy can help doctors find and follow CIDP in people who have or may have the condition.
-
Aging, T cells, and CIDP: how senescence may drive nerveautoimmunity
This grant looks at why CIDP, a chronic autoimmune nerve disease, happens more in older people by studying aging-like changes in immune cells and how they might push nerve cells to become dysfunctional.
-
Understanding B-cell dysfunction in chronic inflammatory demyelinating polyneuropathy
This study is looking into how certain immune cells called B-cells might be causing problems in people with chronic inflammatory demyelinating polyneuropathy (CIDP), with the goal of finding better treatments for this condition.
-
KITE-363 treatment for relapsed or refractory autoimmune neurologic diseases
This study will test whether KITE-363 is safe and can help people with relapsed or treatment-resistant autoimmune neurologic diseases such as MS, CIDP, and myasthenia gravis.
-
Immunoadsorption treatment for chronic inflammatory demyelinating polyneuropathy
This observational study will try immunoadsorption as a next-step treatment for adults with CIDP who do not respond well to IVIg or methylprednisolone.
-
Empasiprubart for adults with CIDP
This study will test whether IV empasiprubart helps improve symptoms and is safe for adults with CIDP, with an initial 24-week randomized comparison to placebo followed by two years of empasiprubart for all participants.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.